Results for tag: "Cometriq"

Cometriq (cabozantinib) is a targeted therapy drug used to treat advanced thyroid cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. It is used to treat medullary thyroid cancer (MTC) that has spread to other parts of the body or cannot be removed by surgery. It is also used to treat anaplastic thyroid cancer (ATC) that has spread to other parts of the body or cannot be removed by surgery. Cometriq is approved by the US Food and Drug Administration (FDA) and is available in the United States. It is also approved in the European Union, Canada, and other countries. The Cometriq market is a small but growing market, with a few companies offering the drug. These include Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation. Show Less Read more